Phase 1 Investigational New Drug (IND) Navigator Expert Resources. Trusted Support.

https://www.fda.gov/industry/phase-1-investigational-new-drug-ind-navigator?utm_medium=email&utm_source=govdelivery FDA Actions to Accelerate and Modernize Clinical Drug Development Today, the FDA is announcing actions to accelerate and modernize clinical research across the full continuum of drug development —from the pre-Investigational New Drug (IND) phase to late-stage pivotal trials. The agency is eliminating unnecessary regulatory burden, clarifying phase-appropriate requirements and building partnerships with government, academic medical centers and the private sector. The FDA is committed to ensuring the United States remains the global standard for pharmaceutical innovation and regulatory rigor. Today’s actions are part of Operation TrialBlazer, a U.S. Department of Health and Human Services (HHS) initiative. FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development?utm_medium=email&utm_source=govdelivery